|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Surgical Intensive Care Unit, National Cardiovascular Center, Osaka, Japan.
Correspondence to: Hideaki Imanaka, MD, Surgical Intensive Care Unit, National Cardiovascular Center, 57-1 Fujishiro-dai, Suita, Osaka, Japan 565-8565; e-mail: imanakah{at}hsp.ncvc.go.jp
| Abstract |
|---|
|
|
|---|
Design: Prospective crossover clinical study.
Setting: Surgical ICU in a national education and research hospital.
Patients: Seven patients (mean age ± SD, 54 ± 11 years) who underwent elective pulmonary thromboendarterectomy for chronic pulmonary thromboembolism.
Interventions: Patients breathed 20 parts per million of NO gas for 30 min at 12-h intervals until extubation of the trachea.
Measurements and results: Hemodynamics and arterial blood gas levels were analyzed before, during, and after NO inhalation. Waveform of pulmonary artery pressure (PAP) was evaluated using fractional pulse pressure (PPf): (systolic PAP - diastolic PAP)/mean PAP. After surgery, pulmonary vascular resistance decreased, PPf decreased, and cardiac index increased significantly. At the first trial, NO inhalation resulted in a slight improvement in arterial oxygen tension (from 173 ± 33 to 196 ± 44 mm Hg; p < 0.05), while hemodynamics did not change significantly. Twelve hours later, NO inhalation decreased pulmonary vascular resistance index (from 312 ± 98 to 277 ± 93 dyne·s·cm-5/m2; p < 0.01), while the change in oxygenation was not significant.
Conclusions: Immediately after pulmonary thromboendarterectomy for chronic pulmonary thromboembolism, NO inhalation improved oxygenation; at 12 h after surgery, NO inhalation resulted in decreased pulmonary vascular resistance, although both changes were small.
Key Words: chronic pulmonary thromboembolism fractional pulse pressure nitric oxide inhalation pulmonary thromboendarterectomy
| Introduction |
|---|
|
|
|---|
Inhaled nitric oxide (NO) is a potent pulmonary vasodilator. NO inhalation can decrease pulmonary vascular resistance (PVR) associated with minimally affecting systemic vascular resistance in ARDS,12 13 postcardiac surgery pulmonary hypertension,14 primary pulmonary hypertension,15 and persistent pulmonary hypertension of the newborn.16 Therefore, NO inhalation might be expected to decrease PVR after PTE, without causing hemodynamic instabilities. In fact, some case reports have suggested that NO inhalation improves postsurgical pulmonary hypertension and hypoxia after PTE.17 18 There have been, however, no systematic studies to determine the effects of NO inhalation on hemodynamics and gas exchange after PTE for CPTE.
To test the hypothesis that NO inhalation improves hemodynamics and gas exchange after PTE for CPTE, we designed a prospective study of patients.
| Materials and Methods |
|---|
|
|
|---|
Preoperatively, the patients demonstrated hypoxia at rest (PaO2, 38.9 to 69.8 mm Hg), dyspnea, and, with New York Heart Association (NYHA) functional class II in one patient and class III in six patients, restricted activity (Table 1 ). Six patients required oxygen therapy at home. Cardiac catheterization showed marked pulmonary hypertension (systolic pulmonary artery pressure [PAP], 74.0 ± 15.3 mm Hg) and low cardiac index (1.89 ± 0.34 L/min/m2; Table 2 ). Lung perfusion scintigrams revealed, in four patients, multiple defects in both lungs; in three patients, multiple defects were found, mainly in the right lung. Pulmonary arteriograms revealed occlusion and stenosis from the lobar to segmental arteries. Deep vein thrombosis was established in all patients. Three patients showed hyperlipidemia, and another had blood coagulation abnormalities with deficiencies of protein C, protein S, and antithrombin III.
|
|
When the patients were admitted to the ICU, they were sedated with IV administration of fentanyl, 0.5 to 1 g/kg/h, at least for 12 h. On admission to the ICU, prostaglandin E1, 26 ± 9 ng/kg/min, was administered in all patients; nitroglycerin, 0.42 ± 0.21 µg/kg/min, in five patients; and dobutamine, 5.3 ± 2.7 µg/kg/min, in six patients. These sedatives and vasodilators were adjusted by attending physicians independently of the study protocol, although their dosages were fixed during each measurement.
The mechanical ventilation settings (model 8400STi; Bird Products; Palm Springs, CA) were as follows: synchronized intermittent mandatory ventilation (SIMV), pressure-controlled ventilation (PCV), respiratory rate of 10 to 15 breaths/min, and pressure support ventilation (PSV) of 10 cm H2O. We adjusted the pressure control level and fraction of inspired oxygen (FIO2) to obtain a tidal volume of 10 mL/kg and PaO2 > 100 mm Hg. The respiratory rate was adjusted to keep mild hypocapnia (PaCO2 of about 35 to 40 mm Hg). In practice, the initial settings were as follows: SIMV rate, 11.6 ± 2.4 breaths/min; PCV, 14.7 ± 2.8 cm H2O; and FIO2, 0.59 ± 0.17. Our ventilatory weaning policy was to decrease the SIMV rate, to decrease FIO2 to < 0.5, and then to evaluate respiratory condition with PSV of 7 to 10 cm H2O; if judged appropriate, endotracheal tubes were removed.19 We chose pressure-limit ventilation modes such as PCV and PSV because the restriction of peak inspiratory pressure was necessary to prevent barotrauma.20
Protocols
After waiting 2 to 3 h for hemodynamics to stabilize after
surgery, we started the measurements. After baseline measurements
remained stable for 30 min, the first preinhalation data were
collected. Then, inhalation of NO was carried out in a crossover
fashion. Inhalation of NO at 20 parts per million (ppm) was instituted
for 30 min, and data were collected. In addition, 30 min after the
termination of NO inhalation, a third set of measurements was taken.
This on/off trial of NO inhalation was repeated every 12 h until
the patient was extubated.
The NO inhalation delivery system has been described elsewhere.13 21 Briefly, 400 ppm of NO in N2 (Kyoto Medical Gas KK; Kyoto, Japan) was mixed with air using an oxygen/air blender (Bird Products). The blender outlet was connected to the high-pressure air inlet of the ventilator. The blender was adjusted to deliver 20 ppm of NO. The inspired NO concentration was analyzed with an NO analyzer (NOA280; Sievers Instruments; Boulder, CO). Constant FIO2 was maintained during each measurement using a medical gas analyzer (M1025B; Hewlett Packard; Andover, MA). Ventilatory parameters, including FIO2, positive end-expiratory pressure (PEEP), PCV level, and minute ventilation, were maintained constant during each NO trial.
Parameters
BP was measured at the radial artery. A 7.5F Swan-Ganz catheter
(Abbott Laboratories; North Chicago, IL) was inserted at the right
common jugular vein. Cardiac output was measured with a thermodilution
technique by injecting 10 mL of cold saline solution. This procedure
was repeated four or five times and averaged. BP, PAP, central venous
pressure, and ECG data were digitally stored at a sampling rate of 200
Hz/channel using Windaq data acquisition software (Dataq Instruments;
Akron, OH). The pressures were calibrated to 50 mm Hg using a mercury
manometer. Systolic, diastolic, and mean PAP data were obtained at end
expiration. Five measurements were performed and averaged. To evaluate
the pulsatility of the pulmonary artery, we calculated the
fractional pulse pressure (PPf) as follows: PPf = (systolic
PAP - diastolic PAP)/mean PAP.22
Reports suggest
that PPf is a key value in interpreting PAP wave form and in
differentiating CPTE from primary pulmonary
hypertension.22
23
CPTE involves a relatively proximal
section of the pulmonary artery, and we speculate that pathologic
changes caused by PTE surgery may cause changes in the PAP waveform and
in PPf.
Statistical Analysis
Data are shown as mean ± SD. Analysis of variance was used to
compare the means of different conditions. Where applicable, post
hoc analysis was performed using a two-tailed paired t
test with Bonferronis correction. Statistical significance was
accepted at a level of p < 0.05.
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
12 h after surgery it
decreased PVR without a significant change in oxygenation.
PTE and Clinical Implication of NO Inhalation
Our findings that hemodynamics and gas exchange improve in CPTE
patients after PTE correlate with reports of San Diego group (Table 2)
.2
3
4
24
PTE has been widely performed as surgical
treatment; however, reperfusion lung edema resulting in hypoxia and the
need for prolonged mechanical ventilation is a common postoperative
complication.7
Several mechanisms have been suggested to
account for pulmonary hypertension that occurs even when thrombi in the
proximal pulmonary artery have been successfully removed after PTE.
Reperfusion lung edema itself can cause pulmonary
hypertension.7
The adverse effects of cardiopulmonary
bypass may also result in pulmonary hypertension.14
The
remodeling of small distal arteries in nonoccluded areas may be
associated with pulmonary hypertension in CPTE, because pulmonary
hypertension is more severe in CPTE than in acute pulmonary embolism
even with comparable degrees of vascular obstruction.8
Moser and Bloor10
have reported pulmonary hypertensive
changes in the small pulmonary arteries downstream from nonthrombosed
arteries.
Several strategies, such as vasodilatation and NO inhalation, are indicated for treating postoperative pulmonary hypertension in CPTE.4 Although the use of vasodilators to prevent pulmonary vasoconstriction makes sense, their use is limited by the adverse systemic vasodilatation associated with hypotension and impairment of myocardial perfusion, which may lead to right ventricular failure.18 On the other hand, inhaled NO is a potent pulmonary vasodilator, and its use is not usually accompanied by severe adverse systemic effects. Thus, inhaled NO is suitable for treating persistent pulmonary hypertension and gas exchange impairment after PTE.17 18
In this prospective study, we found that immediately after PTE, the inhalation of NO improved oxygenation significantly, and it decreased PVR and PAPs in the later phase. An improvement of oxygenation during NO, similarly in ARDS,12 13 may result from redistribution of pulmonary blood flow from poorly ventilated lung units toward well-ventilated ones. Gårdebäck et al17 have reported a case in which reperfusion edema and hypoxia following PTE were successfully treated with NO inhalation. Pinelli et al18 have also reported similar successful treatment with NO in a case of PTE that was followed by acute and persistent pulmonary hypertension, gas exchange impairment, and heart dysfunction. However, as Gårdebäck et al17 suggest, response to NO in CPTE patients may be unpredictable, and depends partly on the degree of mechanical obstruction and partly on the nature of secondary hypertensive changes in otherwise unaffected vessels. After PTE, we also have to consider secondary hypertensive changes even when obstructions have been removed. Consequently, serial evaluation of the effects of NO inhalation after PTE is required. To our knowledge, this is the first report to evaluate effects of NO inhalation periodically in postoperative CPTE patients.
Our study does not offer any evidence as to why the effects of NO inhalation at 12 h after surgery were different from the initial administration. We can, however, suggest several possible reasons. First, each patient had received vasodilators such as prostaglandin E1 and nitroglycerin immediately after the surgery. If this medication had effectively dilated pulmonary vessels, NO inhalation may have less potential to enhance pulmonary vasodilatation. Second, after PTE surgery, the response to NO may have changed differently between in oxygenation and in pulmonary vasodilatation. In ARDS, the concentration of NO that improves oxygenation is lower than that required for pulmonary vasodilatation.12 Reperfusion lung edema after PTE is often compared to localized ARDS,17 so we reason that a similar difference may be manifest after PTE. In other words, it is possible that 20 ppm of NO concentration is not enough for pulmonary vasodilatation, but is sufficient for improving oxygenation in the acute phase, when the greatest adverse effects of cardiopulmonary bypass on pulmonary hypertension are likely to occur.14 In the later period, the vasodilatation response to NO may be more sensitive, resulting in pulmonary vasodilatation, whereas high concentrations of NO may dilate shunt-like vessels and worsen oxygenation, as has been reported in ARDS.12 Gårdebäck et al17 also reported a case in which oxygenation improved during postoperative NO inhalation, despite an unpromising preoperative response to NO of slightly reducing PVR and no improvement of oxygenation.17 Further study is needed to corroborate our observations and to evaluate the effect of NO inhalation on morbidity and mortality.
Clinical Implications of PPf
Immediately after PTE, the PPf of PAP decreased from
1.18 ± 0.14 (Table 2)
to 0.82 ± 0.19 (Table 3)
. In CPTE, thrombi
tend to obstruct the proximal pulmonary arteries, while primary
pulmonary hypertension involves peripheral vessels. These thrombi
attached to the proximal arteries mechanically stiffen the arterial
wall and increase proximal resistance without comparably increasing
peripheral arterial resistance. This type of pathologic change would
increase pulse pressure relative to mean PAP.22
23
Nakayama et al22
have reported that PPf is greater in CPTE
than in primary pulmonary hypertension. We still do not know, however,
whether the PAP waveform in CPTE changes after PTE surgery, or how NO
inhalation affects the waveform after PTE. We speculate that removal of
the proximal thrombi in CPTE mainly decreases proximal resistance,
resulting in lower PPf. In our study, significant decreases in PPf and
mean PAP after PTE suggest that proximal obstruction in CPTE was
successfully removed.
This study includes several limitations. First, the changes we found during NO inhalation were small. Because of small sample size, lack of control group, relatively large standard deviations, and small differences during NO, we are reluctant to extrapolate the findings directly into clinical relevance. Second, because we performed the NO trial only in intubated subjects, firm conclusions can be probably drawn from data measured within the first 12 h. Third, sedatives, vasodilators, and catecholamines were adjusted by attending physicians, although the dosage was fixed during each measurement. Further study is needed to evaluate the interactions between such medications and NO inhalation.
In conclusion, NO inhalation improved oxygenation without significant changes in pulmonary hemodynamics immediately after PTE surgery; at 12 h after surgery, it decreased PVR without significantly changing oxygenation.
| Footnotes |
|---|
Received for publication September 7, 1999. Accepted for publication February 8, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Puis, E. Vandezande, L. Vercaemst, P. Janssens, Y. Taverniers, M. Foulon, R. Demeyere, M. Delcroix, and W. Daenen Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension Perfusion, March 1, 2005; 20(2): 101 - 108. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |